drugset / Trial / NCT07124468

Assess the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Meropenem-Pralubactam (Meropenem/FL058) in China Healthy Adult Participants

NCT07124468

Phase 1 Recruiting 16 enrolled Qilu Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelBasic science

Summary

The goal of this clinical trial is to evaluate the Epithelial Lining Fluid concentrations and permeability of Intravenous Meropenem-Pralubactam(Meropenem/FL058) in China Healthy Adult Participants. The main question it aims to answer is: • \[question 1\] : What are the concentrations of meropenem and Pralubactam in plasma, epithelial lining fluid (ELF), and alveolar macrophages (AM) at each time point

Timeline

Start
2025-09-13
Primary completion
2025-12
Completion
2026-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Meropenem Small molecule Intravenous
Subject Pralubactam Unknown Intravenous

Indications